{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.4","upperLimit":"30.9","value":"23.8"},{"comment":"NA= Median and upper limit not reached at time of data cut-off due to insufficient number of participants with an event.","groupId":"OG001","lowerLimit":"33.3","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"105"},{"groupId":"OG001","value":"54"}],"units":"Participants"}],"description":"OS was defined as the time from first dose of study treatment to death due to any cause. The OS for all participants is presented.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 doses (approximately 24 months).","id":"OG000","title":"Recurrent or Metastatic Cutaneous cSCC Cohort"},{"description":"Participants received pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 doses (approximately 24 months).","id":"OG001","title":"Locally Advanced Unresectable cSCC Cohort"}],"paramType":"MEDIAN","populationDescription":"The analysis population consisted of all participants who received ≥1 dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Up to approximately 56 months","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}